Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers

秋田, 貴博

WEKO3

lat lon distance

[[sub_check.contents]]

[[sub_radio.contents]]

Field does not validate

[[sub_attr.contents]]　

インデックスツリー

アイテム

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers

http://hdl.handle.net/10129/0002000718

名前 / ファイル	ライセンス	アクション
本文 (1.6 MB)
内容要旨 (175 KB)
審査要旨 (166 KB)

Item type

リポジトリ登録用アイテムタイプ（シンプル）(1)

公開日

2024-12-25

タイトル

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers

言語

eng

キーワード

言語

主題Scheme

Other

主題

ALK-positive lung cancer

キーワード

言語

主題Scheme

Other

主題

CEA

キーワード

言語

主題Scheme

Other

主題

CYFRA21-1

キーワード

言語

主題Scheme

Other

主題

EGFR-positive lung cancer

キーワード

言語

主題Scheme

Other

主題

tumor marker

資源タイプ

資源タイプ識別子（シンプル）

http://purl.org/coar/resource_type/c_db06

資源タイプ（シンプル）

doctoral thesis

アクセス権

open access

アクセス権URI

http://purl.org/coar/access_right/c_abf2

著者

秋田, 貴博

抄録

内容記述タイプ

Abstract

内容記述

Background: It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely genetic testing and intervention.
Methods: We selected 134 cases of advanced or recurrent ALK-positive and 172 cases of advanced or recurrent EGFR-positive lung cancer from our clinical database. The cutoff values for the tumor markers were defined as 5.0 ng/mL or higher for carcinoembryonic antigen (CEA) and 3.5 ng/mL or higher for soluble fragment of cytokeratin 19 (CYFRA21-1) in accordance with the institutional standards. A positive CYFRA21-1:CEA ratio was defined as 0.7 or higher.
Results: The CEA-positivity rate was 49% for ALK-positive lung cancers and 73% for EGFR-positive lung cancers, which was significantly different (p < 0.001). The CYFRA21-1 positivity rate was significantly higher in ALK-positive lung cancer (36%) compared with EGFR-positive lung cancer (23%) (p = 0.034). The median CYFRA21-1:CEA ratio was 0.395 for the ALK group, which was significantly higher compared with 0.098 for the EGFR group (p < 0.001). These trends were similar when excluding histology other than adenocarcinoma. The median time-to-treatment failure (TTF) for initial tyrosine kinase inhibitor (TKI) therapy was 308 days for the high CYFRA21-1:CEA ratio group and 617 days for the low CYFRA21-1:CEA ratio group for ALK-positive lung cancer (p = 0.100).
Conclusions: A higher proportion of patients with ALK-positive lung cancer were CYFRA21-1 positive and had higher CYFRA21-1:CEA ratios compared with EGFRpositive lung cancer patients.

言語

内容記述

内容記述タイプ

Other

内容記述

Author: Takahiro Akita, Ryo Ariyasu, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio

言語

内容記述

内容記述タイプ

Other

内容記述

Citation: Thoracic Cancer 15(10):788-796, 2024.

言語

書誌情報

en : Thoracic Cancer

巻 15, 号 10, p. 788-796, 発行日 2024-02-24

ISSN

収録物識別子タイプ

EISSN

収録物識別子

1759-7714

DOI

Versions

Ver.1

2024-12-25 05:28:06.718456

Show All versions

Cite as

エクスポート

OAI-PMH

JPCOAR 2.0
JPCOAR 1.0
DublinCore
DDI

Other Formats

JSON
BIBTEX

インデックスリンク

インデックスツリー

アイテム

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers

× 秋田, 貴博

Versions

Share

Cite as

エクスポート